Icon

Icon expands U.S. and U.K. bioanalytical labs

Monday, September 10, 2012 09:48 AM

Icon,a global provider of outsourced development services, is expanding its U.S. and U.K. bioanalytical facilities to meet the growing demand for biomarker and cell-based assay services.

Icon has increased its bioanalytical laboratories in Whitesboro, N.Y., and Manchester, U.K., by 7,000 and 4,000 square feet, respectively. The expansions allow Icon to house dedicated immunoassay laboratories at each facility for biomarker testing and cell-based assays.

More... »

Icon forms partnership with University College Dublin

Wednesday, September 5, 2012 10:13 AM

Icon,a global provider of outsourced development services, has entered into a strategic partnership with University College Dublin (UCD), Ireland’s largest third-level institution.

More... »

Icon to expand hospital-based presence in translational medicine

Wednesday, August 8, 2012 10:26 AM

Icon, a global provider of outsourced development services, has announced plans to further expand its U.K. hospital-based presence on the Manchester Royal Infirmary Campus.

More... »

Icon appoints three to senior clinical and laboratory positions

Tuesday, July 3, 2012 10:49 AM

Icon,a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, has appointed three additions to the senior management teams of its clinical and central laboratories businesses.

More... »

Icon selects AG Mednet to give trial sponsors zero-delay efficiency

Wednesday, June 27, 2012 09:23 AM

AG Mednet has signed an OEM agreement with Icon Medical Imaging, a division of Icon, further embedding AG Mednet’s quality control, compliance, de-identification and image transfer technology into Icon’s imaging trial offerings.

More... »

Lexicon touts significant results for LX4211 phase IIb trial in T2D

Monday, June 25, 2012 03:50 PM

Lexicon Pharmaceuticals of The Woodlands, Texas, has reported that LX4211, an investigational, oral, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2), showed substantial, dose-dependent, statistically-significant reductions in hemoglobin A1c (HbA1c) in a phase IIb trial in patients diagnosed with poorly-controlled type 2 diabetes who were concurrently treated with metformin, an established diabetes therapy.

More... »

ExecuPharm expands to U.K. and Argentina

Thursday, June 21, 2012 02:49 PM

ExecuPharm, a staffing and functional service providers (FSP) specializing solely in the clinical research industry, recently expanded its locations to include Europe and Latin America.

More... »

Icon makes senior appointments

Monday, May 21, 2012 11:52 AM

Icon, a global provider of outsourced development services, has appointed Dr. Susan Anton as director of epidemiology and risk management practice, Icon late phase & outcomes research, and Dr. Pui Leung as senior clinical research physician, Icon Development Solutions.

More... »

J&J China acquires Guangzhou Bioseal Biotech

Friday, May 4, 2012 08:01 AM

Johnson & Johnson China Investment has acquired Guangzhou Bioseal Biotech, a privately held biopharmaceutical company specializing in the design, development and commercialization of a porcine plasma-derived biologic product for controlling bleeding during surgery. Financial terms of the transaction are not being disclosed. 

More... »

Icon reports 10% increase in Q1 2012

Wednesday, April 25, 2012 09:45 AM

Icon, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, has released its first quarter financial results for 2012, reporting its Q1 net revenues grew 10% year on year to $252.3 million from $229.3 million in Q1 2011.

More... »